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Abstract
Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated
combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev),
sunitinib (Su) and EMAP II. Cell proliferation and protein expression were analyzed by WST-1 assay and Western blotting. In
vivo experiments were performed via murine xenografts. Inhibition of in vitro proliferation of AsPC-1 PDAC cells by
gemcitabine (10 mM), bevacizumab (1 mg/ml), sunitinib (10 mM) and EMAP (10 mM) was 35, 22, 81 and 6 percent;
combination of gemcitabine with bevacizumab, sunitinib or EMAP had no additive effects. In endothelial HUVECs,
gemcitabine, bevacizumab, sunitinib and EMAP caused 70, 41, 86 and 67 percent inhibition, while combination of
gemcitabine with bevacizumab, sunitinib or EMAP had additive effects. In WI-38 fibroblasts, gemcitabine, bevacizumab,
sunitinib and EMAP caused 79, 58, 80 and 29 percent inhibition, with additive effects in combination as well. Net in vivo
tumor growth inhibition in gemcitabine, bevacizumab, sunitinib and EMAP monotherapy was 43, 38, 94 and 46 percent;
dual combinations of Gem+Bev, Gem+Su and Gem+EMAP led to 69, 99 and 64 percent inhibition. Combinations of more
than one antiangiogenic agent with gemcitabine were generally more effective but not superior to Gem+Su. Intratumoral
proliferation, apoptosis and microvessel density findings correlated with tumor growth inhibition data. Median animal
survival was increased by gemcitabine (26 days) but not by bevacizumab, sunitinib or EMAP monotherapy compared to
controls (19 days). Gemcitabine combinations with bevacizumab, sunitinib or EMAP improved survival to similar extent (36
or 37 days). Combinations of gemcitabine with Bev+EMAP (43 days) or with Bev+Su+EMAP (46 days) led to the maximum
survival benefit observed. Combination of antiangiogenic agents improves gemcitabine response, with sunitinib inducing
the strongest effect. These findings demonstrate advantages of combining multi-targeting agents with standard
gemcitabine therapy for PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive human cancers and remains the fourth leading cause of
cancer-related deaths in the United States. Rapid tumor
progression, late diagnosis, early and aggressive metastasis and
high resistance to conventional chemotherapy leads to exception-
ally poor prognosis with a 5-year survival rate less than 5% [1].
Treatment of PDAC depends on the stage of the cancer; the
overall resectability rate is only 10 to 15%, and postoperative
recurrence is common [2,3,4]. Much attention has been focused
towards systemic treatment options for PDAC for possible
definitive or perioperative therapy benefit. Gemcitabine (Gem), a
deoxycytidine nucleoside analog, is a cytotoxic agent that causes
inhibition of DNA synthesis and cell death. The Food and Drug
Administration (FDA) approved gemcitabine for the treatment of
advanced PDAC in 1997. However, gemcitabine is clinically
effective only in 20–30% of PDAC patients, leading to a median
progression free survival of 5.7 months compared with 4.4 months
in the 5-fluorouracil treated group [5]. Gemcitabine-based
combination chemotherapy regimens have failed to show any
meaningful survival advantage over single agent gemcitabine [6,7].
These facts clearly demonstrate the urgent need for novel and
more effective therapeutic strategies for PDAC.
Angiogenesis, a process by which tumors acquire blood supply
for their continued growth, is essential for the progression of
primary and metastatic solid tumors including PDAC. Angiogen-
esis is initiated by hypoxia, growth factors, cytokines, and
activation of proto-oncogene and de-activation of tumor suppres-
sor gene mechanisms [8]. Targeting angiogenesis to reduce tumor
progression and metastasis may yield novel approach for
combination therapy. Antiangiogenic agents such as anti-vascular
endothelial growth factor (VEGF) agent bevacizumab (Bev),
matrix metalloproteinase inhibitors (marimastat) and cyclooxy-
genase inhibitors (Celecoxib) have been studied in combination
therapy in PDAC models with limited survival benefit [9,10,11].
Erlotinib, the epidermal growth factor receptor inhibitor, has to
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benefit in combination with gemcitabine [12].
ManyreportsintheliteraturesuggestthatVEGFsignalingplaysan
important role in PDAC progression [13,14,15,16]. Therefore
bevacizumab, a recombinant humanized monoclonal antibody
againstVEGF,wasevaluatedinphaseIIandphaseIIIclinicaltrials.
Although the bevacizumab and gemcitabine combination showed
some promise in a phase II trial, no significant improvement was
observedinsubsequentphaseIIIstudies[17].Sunitinib(Su)isamulti-
target receptor tyrosine kinase (RTK) inhibitor with antiangiogenic
and antitumor activities [18,19,20]. Sunitinib inhibits RTKs
expressedbytumorcellsthatareinvolvedintumorcellproliferation
andsurvivalincludingstemcellfactorreceptor(c-KIT),Fms-related
tyrosine kinase 3 (FLT3), the glial cell-line derived neurotrophic
factor receptor (RET) and colony-stimulating factor type 1 receptor
(CSF-1R) [18,19]. Sunitinib also inhibits RTKs expressed on
endothelial and mural cells, such as VEGF receptors (type 1 and 2)
andplatelet-derivedgrowthfactor(PDGF)receptorsaandb[20,21].
In human PDAC, VEGF receptors and PDGF receptors are over-
expressedandhavebeencorrelatedwithpoorprognosis[22,23,24].
Sunitinibhasbeenshowntohaveantitumorefficacyinexperimental
PDAC [25,26,27]. Endothelial monocyte activating polypeptide II
(EMAP) is a proinflammatory cytokine with antiangiogenic and
antiendothelial activities. EMAP has potent effects on endothelial
cells (ECs) such as inhibition of proliferation, migration and
vascularization as well as induction of apoptosis [28,29]. EMAP
suppresses primary and metastatic tumor growth [28,30,31] that
could be related to its ability to bind VEGF receptors and a5b1
integrin, leading to an interference in fibronectin- and VEGF
signaling [32,33]. EMAP has recently been shown to improve
gemcitabine and docetaxel response in experimental PDAC
[34,35,36].Thepresentstudyevaluatedandcomparedcombination
treatment benefits of gemcitabine with three antiangiogenic agents
bevacizumab, sunitinibandEMAPforpotentially enhancedPDAC
clinical applications.
Materials and Methods
Materials
Gemcitabine was purchased from Eli Lilly (Indianapolis, IN).
Bevacizumab was purchased from Genentech (South San
Francisco, CA). Sunitinib was purchased from LC Laboratories,
Inc. (Woburn, MA). Recombinant human EMAP was prepared as
previously described [37], while the cell proliferation reagent
WST-1 was purchased from Roche Diagnostic Corporation
(Indianapolis, IN).
Cell Culture
The human pancreatic cancer cell line AsPC-1, human
fibroblast cell line WI-38 and human umbilical vein endothelial
cells (HUVECs) were all purchased from the American Type
Culture Collection (ATCC, Rockville, MD). AsPC-1 and WI-38
cells were grown in RPMI 1640 medium and DMEM, respectively
(Sigma Chemical Co. St. Louis, MO) supplemented with 10%
fetal bovine serum (FBS). HUVECs were grown in EndoGRO-LS
medium containing endothelial cell growth supplements (Millipore
Corp., Billerica, MA).
Cell Viability Assay
In vitro cell viability was evaluated by the WST-1 assay. Four
thousand cells were plated in a 96-well plate and after 16 hours the
medium was replaced with low serum containing medium. Cells
Table 1. Percentage of cell viability in AsPC-1, HUVECs and WI-38 cells exposed to Gem, Bev, Su and EMAP, either alone or in
combination.
Treatments and
Combinations AsPC-1 HUVECs WI-38
Dose levels Dose Levels Dose levels
ABCDABCDABC D
Gem alone 91612 85677 3 666 5 612 58674 2 653 8 643 0 633 9 642 9 622 6 632 1 61
Bev alone 94658 8 657 5 637 8 659 0 688 4 686 4 685 9 691 0 0 649 3 646 6 624 2 63
Su alone 100699 4 667 8 661 9 644 7 684 4 663 8 611 4 671 0 9 689 9 618 3 622 0 62
EMAP alone 96613 91658 9 639 4 698 8 623 47617 37643 3 610 82627 7 617 6 617 1 62
Gem+Bev 86611 71677 0 636 7 683 2 613 28662 4 621 6 623 8 622 7 612 4 631 7 62
Gem+Su 79655 9 665 5 611 9 644 3 613 31622 9 618 653 9 632 8 612 1 611 6 63
Gem+EMAP 84678 3 677 2 611 61611 42653 3 613 7 612 2 664 8 653 1 612 5 621 8 62
Bev+Su 80616 64625 7 632 2 616 4 684 9 663 5 631 8 628 1 610 73664 6 612 1 62
Bev+EMAP 108651 0 4 641 0 7 679 8 656 2 675 5 643 6 611 24651 1 3 691 0 6 697 3 624 0 65
Su+EMAP 100669 6 610 81612 2 686 0 665 9 665 3 672 6 610 75626 7 636 7 672 0 61
Gem+Bev+Su 83657 5 645 9 642 7 635 4 613 38653 2 672 0 643 4 612 4 632 0 611 7 63
Gem+Bev+EMAP 85618 1 617 6 686 7 695 0 663 9 623 7 643 3 663 4 643 0 612 4 621 7 62
Gem+Su+EMAP 81637 6 626 5 652 1 615 0 674 8 633 9 662 5 653 6 632 4 611 9 611 7 62
Bev+Su+EMAP 94687 0 635 7 631 7 638 0 667 4 615 3 642 3 648 4 657 3 664 4 632 0 62
Gem+Bev+Su+EMAP 82677 7 686 3 611 22626 1 625 3 644 8 662 1 645 3 633 5 613 0 612 1 62
Cells were seeded into 96-well plates and treated with Gem, Bev, Su and EMAP. A represents 100 nM for Gem, Su, E and 1 mg/ml for Bev; B represents 500 nM for Gem,
Su, E and 10 mg/ml for Bev; C represents 1 mM for Gem, Su, E and 100 mg/ml for Bev; D represents 10 mM for Gem, Su, E and 1000 mg/ml for Bev. After 72 hours
incubation, 10 ml WST-1 reagent was added to each well, and absorbance of color produced was measured at 450 nm that correlates with the number of viable cells in
the well. Data are expressed as the mean value 6 standard deviation of quadruplicate determinants.
doi:10.1371/journal.pone.0038477.t001
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EMAP. The range of concentrations used for gemcitabine,
sunitinib and EMAP (10 nM to 10 mM); and for bevacizumab
(1 mg/ml to 1 mg/ml) was comparable to clinically achievable
concentrations. After a 72-hour incubation, 10 ml WST-1 reagent
was added in each well, and absorbance at 450 nm was measured
after 2 hours using a microplate reader.
Western Blot Analysis
A sub-confluent cell monolayer was treated with gemcitabine
(10 mM), bevacizumab (1 mg/ml), sunitinib (10 mM) or EMAP
(10 mM) and incubated 12 hours for HUVECs and 24 hours for
AsPC-1 and WI-38 cells. Total cell lysate was prepared, protein
concentration measured and equal amounts of protein were
separated by SDS-PAGE and transferred to PVDF membranes
(Bio-Rad, Hercules, CA). The membranes were blocked for 1
hour in blocking solution (5% milk in TBS-T [Tris-buffered
saline containing Tween-20]) and incubated overnight at 4uC
with the following antibodies: cleaved poly (ADP-ribose)
polymerase-1 (PARP-1), cleaved caspase-3 (Cell Signaling
Technology, Beverly, MA) or a-tubulin (Sigma). The mem-
branes were then incubated with corresponding HRP-conjugat-
ed secondary antibodies (Pierce Biotechnologies, Santa Cruz,
CA) for 1 hour at room temperature. Specific bands were
detected using the enhanced chemiluminescence reagent (ECL,
Perkin Elmer Life Sciences, Boston, MA) on autoradiographic
film and quantitated by densitometry.
Tumor Implantation and in vivo Tumor Growth
Experiment
All animal procedures and care were performed according to
the guidelines and approved protocols of the University of Texas
Southwestern Medical Center (Dallas, TX) Institutional Animal
Care and Use Committee (Animal Protocol Number 2008-0348).
Athymic female nude mice (aged 4–8 weeks) were used in
subcutaneous xenograft model. Human pancreatic cancer AsPC-1
cells (0.75610
6) were subcutaneously injected in each mouse. After
14 days when all mice had measurable tumor, mice were
Figure 1. Evaluation of PARP-1 and caspase-3 cleavage. AsPC-1, HUVECs and WI-38 cell cultures were treated with Gem (10 mM), Bev (1 mg/
ml), Su (10 mM) and EMAP (10 mM), either alone or in combination for 16 hours. Total cell lysate from treatment groups was subjected to SDS-PAGE
and immunoblotting. Expression of a-tubulin was analyzed as internal loading control. Data are representative of two independent experiments with
similar results.
doi:10.1371/journal.pone.0038477.g001
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toneally with PBS (control), gemcitabine (100 mg/kg, twice
weekly), bevacizumab (10 mg per mouse, twice weekly), sunitinib
(40 mg/kg for 1
st week, 20 mg/kg for 2
nd week, 5 times weekly)
and EMAP (80 mg/kg, 5 times weekly) for 2 weeks. The tumor size
in all mice was measured twice weekly by caliper. Tumor volume
(V) was calculated by using the formula [V=K (L6(W)
2], where
L=length and W=width. Net growth in tumor size was
calculated for each animal by subtracting tumor volume on the
first day of treatment from that on the last day. After completion of
treatment, all animals were euthanized, tumors were removed,
weighed, dissected and processed for histological or immunohis-
tochemical analysis.
Histology and Immunohistochemical Analysis
Tumor tissue specimens fixed in 4% paraformaldehyde and
embedded in paraffin were used for histological and immuno-
histological analysis. Intratumoral proliferative activity was
measured using by Ki67 nuclear antigen staining as per
manufacturer’s protocol (Abcam, Cambridge, MA). Briefly,
paraffin-embedded tumor tissue sections were cut, deparaffi-
nized, rehydrated and antigen retrieved. The tissue sections
were incubated with CAS blocking buffer followed by 1-hour
incubation with Ki67 antibody (1:200 dilution). The tissue
sections were then incubated with Cy3 (1:200 dilution)
secondary antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA) for 40 minutes. Slides were mounted using
mounting solution containing 49,6-diamidino-2-phenylindole
(DAPI) (Invitrogen, Carlsbad, CA). Proliferative activity was
evaluated by calculating Ki67-positive cells from five different
high-power fields (HPF) in a blinded manner. For detecting
microvessel density (MVD), tissue sections were incubated with
1:100 dilution of PECAM-1 (CD-31) antibody (BD Pharmingen,
Bedford, MA) overnight at 4uC. The tissue sections were then
incubated with 1:200 dilution of Cy3 secondary antibody for 40
minutes. Slides were mounted using mounting solution contain-
ing DAPI, and MVD was evaluated by counting PECAM-1
positive vessels within a microscopic HPF in a blinded manner.
Intratumoral apoptosis was analyzed by staining tissue sections
with ‘‘Apoptag Apoptosis Detection Kit’’ according to the
manufacturer’s (Millipore) instructions. Fluorescence microscopy
was used to detect fluorescent signals using IX81 Olympus
microscope and images were captured with a Hamamatsu Orca
digital camera (Hamamatsu Corporation, Bridgewater, NJ) with
a DSU spinning confocal unit using Slidebook software
(Intelligent Imaging Innovations, Philadelphia, PA).
Animal Survival Analysis
Animal survival studies were performed using 6- to 8-week-
old female SCID mice [38]. AsPC-1 (0.75610
6) cells were
injected intraperitoneally in each mouse and after two weeks
mice were randomly grouped (n=6 to 8 per group) and treated
intraperitoneally with PBS (control), gemcitabine (100 mg/kg,
twice weekly), bevacizumab (10 mg per mouse, twice weekly),
sunitinib (40 mg/kg for 1
st week, 20 mg/kg for 2
nd week, 5
times weekly) or EMAP (80 mg/kg, 5 times weekly) for 2 weeks.
Animals were euthanized when turning moribund according to
predefined criteria including rapid weight loss or gain (.15%),
tumor size, lethargy, inability to remain upright and lack of
strength. Survival was evaluated from the first day of treatment
until death.
Statistical Analysis
Statistical significance wasanalyzed bythetwo-tailed Student’st-
test using GraphPad Prism 4 Software (GraphPad Software, San
Diego, CA). In vitro cell proliferation data are expressed as mean 6
standard deviation. Additivity of the drug combinations was
determined by calculating an ‘‘interaction index’’ using the Chou
TC, Talalay P [39] and Lee JJ [40] methods. Statistical analysis for
in vivo studies was performed by ANOVA for multiple group
comparison and Student’s t-test for the individual group compar-
ison. Survival study statistics were evaluated with StatView for
Figure 2. In vivo inhibition of local tumor growth. Nude mice were subcutaneously injected with AsPC-1 cell (0.75610
6) and treated with Gem,
Bev, Su and EMAP, either alone or in combination, for 2 weeks. Tumor growth was measured 2 times a week using calipers, and net tumor growth
was calculated by subtracting tumor volume on the first treatment day from that on the final day. Data are representative of mean values from 6–8
mice per group.
doi:10.1371/journal.pone.0038477.g002
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and logrank testing. Values of p,0.05 were considered to represent
statistically significant group differences.
Results
Effect of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Cell Proliferation
In vitro cell proliferation analysis in AsPC-1 cells by
gemcitabine (10 mM), bevacizumab (1 mg/ml), sunitinib (10 mM)
and EMAP (10 mM) showed 35, 22, 81 and 6 percent inhibition in
cell proliferation, respectively. Combinations of gemcitabine with
single antiangiogenic agents bevacizumab or EMAP had no
additive effects, while the combination of gemcitabine with
sunitinib could not surpass the effects of single agent sunitinib.
Combinations of more than one antiangiogenic agent with
gemcitabine had no additive in vitro effects (Table 1). Although
gemcitabine had various effects on the other PDAC cell lines
BxPC-3, MIA PaCa-2 and Panc-1, the effects of combinations of
antiangiogenic agents had similar results as those observed with
AsPC-1 (data not shown).
In HUVECs, gemcitabine (10 mM), bevacizumab (1 mg/ml),
sunitinib (10 mM) and EMAP (10 mM) treatment caused a 70, 41,
86 and 67 percent inhibition in cell proliferation, respectively.
Combinations of gemcitabine with single agent bevacizumab,
sunitinib or EMAP resulted in significant additive effects on
proliferation inhibition. However, combination of more than one
antiangiogenic agent did not have additive effect. In WI-38 cells,
gemcitabine (10 mM), bevacizumab (1 mg/ml), sunitinib (10 mM)
and EMAP (10 mM) caused 79, 58, 80 and 29 percent inhibition in
cell proliferation, respectively. Combination of gemcitabine with
bevacizumab, sunitinib or EMAP had significant additive effect
and combination of more than one antiangiogenic agents to
gemcitabine had no further additive effects (Table 1). For
gemcitabine combinations with different antiangiogenic agents,
the median interaction index was 1.03 (range 0.9 to 1.34) for
AsPC-1 cells, 1.3 (range 1.06 to 2.59) for HUVECs and 1.35
(range 1.06 to 2.47) for WI-38 cells. The interaction indices were
obtained at IC25,I C 50,I C 75 and IC90 levels and were not
significantly different from 1 indicating that in all drug combina-
tions the combined effects were additive.
Effects of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Apoptosis Related Proteins
We examined if the inhibition in cell viability by gemcitabine,
bevacizumab, sunitinib and EMAP could in part be correlated
with induction of apoptosis. Evaluation of PARP-1 cleavage and
caspase-3 cleavage as markers of induction in apoptosis revealed
that in AsPC-1 cells gemcitabine treatment caused a small
increase, bevacizumab and EMAP caused no increase, but
sunitinib treatment led to a significant increase. Combination of
gemcitabine with sunitinib had additive effects (Figure 1). In
HUVECs, gemcitabine, bevacizumab and EMAP caused a small
increase and sunitinib caused a strong increase in PARP-1 and
caspase-3 cleavage. Combinations of gemcitabine with antiangio-
genic agents had additive effects. In WI-38 cells, gemcitabine and
sunitinib both caused an obvious increase; while bevacizumab and
EMAP demonstrated no significant effect on PARP-1 and caspase-
3 cleavage. Combinations of gemcitabine with bevacizumab,
sunitinib and EMAP all had additive effects on cleaved PARP-1
and caspase-3 protein expression (Figure 1).
Effects of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Local Tumor Growth
Subcutaneous murine PDAC xenografts studies showed that
gemcitabine, bevacizumab, sunitinib and EMAP treatment
inhibited local tumor growth, with sunitinib monotherapy having
the strongest effect. Net tumor growth inhibition after a 2-week
treatment with gemcitabine, bevacizumab and sunitinib and
EMAP was 43, 38, 94 and 46 percent, respectively (Figure 2).
Addition of single agent bevacizumab, sunitinib and EMAP to
gemcitabine had additive effects on tumor growth inhibition, as
Gem+Bev, Gem+Su and Gem+EMAP led to 69, 99 and 64
percent tumor growth inhibition. Combinations of more than one
antiangiogenic agent with gemcitabine were also effective but not
significantly better in this experiment than sunitinib alone
(Figure 2, Figure S1). No apparent signs of drug related toxicity
were observed in any treatment group in terms of animal habitus,
activity levels and weight (Figure S2).
Effects of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Intratumoral Proliferative and Apoptotic
Activity
Analysis of Ki67-positive cells as marker of intratumoral
proliferative activity revealed that gemcitabine, bevacizumab,
sunitinib and EMAP monotherapy caused 34, 28, 82 and 22
percent inhibition in the proliferative index. Combinations of
gemcitabine with one or more antiangiogenic agents were effective
but did not enhance inhibition of the intratumoral proliferative
index beyond levels achieved by sunitinib alone (Figure 3).
Evaluation of intratumoral apoptosis by TUNEL-staining
demonstrated small increases in apoptosis by gemcitabine,
bevacizumab and EMAP, and a significant increase by sunitinib
alone. Combinations of bevacizumab and sunitinib or EMAP with
gemcitabine led to increased levels of apoptosis compared with
single agents. Apoptotic indices (TUNEL-positive cells/total cell
per HPF) in controls, and in Gem, Bev, Su, EMAP, Gem+Bev,
Gem+Su, Gem+EMAP groups were 0.1360.03, 0.2160.06,
0.1960.03, 0.4760.05, 0.1860.01, 0.2660.03, 0.5360.01 and
0.2560.02, respectively. Combinations of more than one anti-
angiogenic agent with gemcitabine also increased apoptosis, but
were not significantly more effective than sunitinib alone (Figure 4).
Effects of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Intratumoral Microvessel Density
PECAM-1 staining of tumor tissue sections to study tumor
vasculature revealed that gemcitabine, bevacizumab, sunitinib and
EMAP all caused a significant reduction in microvessel density
compared with control (Figure 5). Sunitinib alone induced the
maximum effect on decreasing MVD among all agents tested.
Combinations of gemcitabine with bevacizumab and EMAP
showed additive effects on decreasing microvessel counts com-
pared with single agents. All combinations with sunitinib were very
Figure 3. Measurement of intratumoral proliferative activity using Ki67 immunostaining. Nude mice were subcutaneously injected with
AsPC-1 cells (0.75610
6) and treated with Gem, Bev, Su and EMAP, either alone or in combination, for 2 weeks. (A) Tumor tissue sections were
immunostained with Ki67 nuclear antigen and photographed under a fluorescent microscope. (B) Ki67-positive cells were counted in five different
high power fields. The data are expressed as the mean 6 standard deviation. SymbolsN and * represent significant differences (P,0.05) compared
with controls and Gem group, respectively.
doi:10.1371/journal.pone.0038477.g003
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were evaluated for mean microvessel counts including, controls
(25.563.5), gemcitabine (14.262.1), bevacizumab (11.862.6),
sunitinib (5.062.3), EMAP (11.162.5), Gem+Bev (7.862),
Gem+Su (5.661.1), Gem+EMAP (7.961.7), Bev+Su (2.961),
Bev+EMAP (8.261.5), Su+EMAP (5.261.5), Gem+Bev+Su
(3.961), Gem+Bev+EMAP (5.561.5), Gem+Su+EMAP
(3.360.6), and Gem+Bev+Su+EMAP (2.961), respectively
(Figure 5).
Effects of Gemcitabine, Bevacizumab, Sunitinib and
EMAP on Animal Survival
PDAC murine xenograft studies in SCID-NOD mice resulted in
a median survival of 19 days in the control group. Median survival
(m.s.) increased modestly after gemcitabine (26 days, p=0.02), but
there was no significant survival benefit with single agent
bevacizumab, sunitinib or EMAP as compared with control.
Combination treatment of gemcitabine with single agent bevaci-
zumab, sunitinib and EMAP all significantly improved animal
survival to a similar extent, with median survivals in the Gem+Bev
group of 36 days (p=0.003 vs. control, 0.006 vs. Gem), after
Gem+Su 37 days (p=0.003 vs. control, 0.01 vs. Gem) and after
Gem+EMAP 36 days (p=0.002 vs. control, 0.001 vs. Gem). The
combination of gemcitabine with Su+EMAP (m.s.=36 days) was
not better than combination of gemcitabine with single agent
sunitinib or EMAP. Combination of gemcitabine with Bev+EMAP
(m.s.=43 days, p=0.001 vs. control, 0.005 vs. Gem) or with
Bev+Su+EMAP (46 days, p=0.001 vs. control, 0.003 vs. Gem)
demonstrated the maximum survival benefit (Figure 6).
Discussion
Pancreatic cancer has an extremely poor prognosis due to late-
stage diagnosis, early metastatic spread and high resistance to
radiation and chemotherapy. Although single agent gemcitabine
therapy has produced some clinical benefits for metastatic PDAC,
the overall survival benefit remains limited [1]. Since angiogenesis
is critical for primary and metastatic PDAC progression,
antiangiogenic treatment is a sensible and still promising
therapeutic avenue due to its potential for synergistic interaction
with other antitumor agents, low toxicity and enhanced antitumor
effect [41,42]. Several growth factors such as VEGF, fibroblast
growth factor (FGF), PDGF or insulin-like growth factor (IGF) are
among the most important angiogenic activators in PDAC
progression. Bevacizumab, the first FDA-approved angiogenesis
inhibitor showed some promise in initial PDAC studies in
combination with gemcitabine but failed to confirm any significant
survival benefit in later studies [17]. Sunitinib, a multitargeted
inhibitor of angiogenic RTKs VEGFR, PDGFR, c-KIT, FLT-3
and RET, is an interesting agent regarding its combination
therapy potential, as compared to narrow-spectrum inhibitors that
have so far shown rather limited clinical activity. Our results show
that 1.: the combination of antiangiogenic agents with gemcitabine
generally yields better results than monotherapy; 2.: the effects of
sunitinib alone can be rather pronounced, at least in the models
tested; 3.: multiple combinations of antiangiogenic agents in
addition to gemcitabine tend to yield the best results; and 4.:
sunitinib and bevacizumab appear to have no obvious combina-
tion benefit.
Tumor progression critically depends on a complex interaction
among several components including tumor cells, immune cells,
ECs, extracellular matrix (ECM) and stromal fibroblasts. Solid
tumor treatment by targeting the EC and fibroblast compartments
within the tumor microenvironment has shown some substantial
benefits [43,44]. EMAP, a tumor-derived antiangiogenic and
antiendothelial cytokine, in our experience exhibited antitumor
effects in several tumor types including PDAC
[28,30,31,34,35,45,46]. The scope of the present study was to
evaluate enhancement of gemcitabine response by combination of
more than one antiangiogenic agents with an entire spectrum of
different mechanisms against PDAC. For instance, we recently
demonstrated that EMAP improves gemcitabine plus bevacizu-
mab combination effects against PDAC [34]. Adding a multi-
TKR targeting agent such as sunitinib appeared therefore sensible.
Gemcitabine had differential growth inhibitory response on PDAC
cells in vitro. Gemcitabine sensitivity was seen in the order of
BxPC-3. MIA PaCa-2.Panc-1. AsPC-1, indicating BxPC-3 as
most sensitive and AsPC-1 as least sensitive cells (Figure S3).
Perhaps this is a rather useful approach that allows the testing of
additional mechanisms for an in vivo combination benefit in
contrast to PDAC lines that are gemcitabine-sensitive. Among
antiangiogenic agents, bevacizumab and EMAP alone had no
meaningful effect on AsPC-1 proliferation, while sunitinib was
very effective. The sunitinib effect was stronger than equimolar
gemcitabine, while addition of two or more antiangiogenic agents
was not more inhibitory than sunitinib alone. As expected, all
three antiangiogenic agents significantly inhibited EC and
fibroblast proliferation in vitro, with sunitinib alone again being
the most effective. In our studies, since sunitinib had maximum in
vitro activity towards tumor cells, ECs and fibroblasts, it supports
the assumption that in vivo antitumor activities of sunitinib may
partially depend upon its impact on tumor cells as well as tumor
vasculature and stromal components, as previously reported
[20,21,47,48]. Mendel et al. [20] showed that the sunitinib IC50
for VEGF- and PGDF-induced HUVECs was in a nanomolar
range. A comparatively weak activity of sunitinib was observed in
the present study; we assume that this is due to the use of full-
growth medium for HUVECs, which could render cells more
resistant to tyrosine kinase inhibitory effects. These results support
the notion that benefits can be derived from combinations of
multi-targeting agents over agents with limited targets alone, or in
addition to them. Gemcitabine and sunitinib have been shown to
induce apoptosis in tumor cells as well as endothelial cells
[49,50,51,52], whereas bevacizumab and EMAP mainly have
proapoptotic activity towards endothelial cells [28,53]. In the
present study, evaluation of induction in apoptosis by gemcitabine
and antiangiogenic agents, either alone or in combination, was
correlated to cell proliferation results indicating that loss in cell
viability by these agents may in part be due to the induction in
apoptosis.
In vivo murine xenograft studies demonstrated that gemcita-
bine, bevacizumab, sunitinib and EMAP inhibited local tumor
growth as single agent. Antitumor effects of bevacizumab and
EMAP are more likely due to their effect on ECs and fibroblasts
Figure 4. Measurement of intratumoral apoptotic activity using TUNEL staining. Nude mice were subcutaneously injected with AsPC-1
cells (0.75610
6) and treated with Gem, Bev, Su and EMAP, either alone or in combination, for 2 weeks. (A) Tumor tissue sections were stained with
TUNEL procedure and photographed under a fluorescent microscope. (B) TUNEL-positive apoptotic cells were counted in five different high power
fields. The data are expressed as the mean 6 standard deviation. SymbolsN and * represent significant differences (P,0.05) compared with controls
and Gem group, respectively.
doi:10.1371/journal.pone.0038477.g004
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agents as monotherapy was limited. Sunitinib as single agent was
very effective, likely due to its broad target spectrum, inhibiting
multiple cellular compartments in the tumor microenvironment.
Despite using less than half the maximum tolerable dose of
sunitinib its high effect could have masked any combination
treatment benefits. A lower dose of sunitinib in the combination
group would have provided more useful evaluation of the effect of
combination treatment. Gemcitabine effects on tumor growth
inhibition were enhanced by the addition of single antiangiogenic
agents, generally supporting the importance of blocking multiple
pathways for the more effective treatment of PDAC. Tumor
growth inhibition results in the present study appear to be
correlated with intratumoral proliferative index, apoptotic index
and microvessel density. However, a predictive factor suggestive of
this specific treatment response cannot be determined due to lack
of a specific mechanism of action and the use of only a single
PDAC cell line. Several distinct mechanisms including induction
of cancer cell proliferation, migration, differentiation, adhesion,
angiogenesis and inhibition of cancer or stromal cell apoptosis are
responsible for active PDAC progression. Gemcitabine has
antiproliferative and proapoptotic effects on tumor cells as well
as ECs and fibroblasts. The exact operational mechanisms for the
enhancement in antitumor activity of gemcitabine in combination
with bevacizumab, sunitinib or EMAP remain unclear; however,
they more likely include normalization of tumor microvessels,
increased delivery of gemcitabine into the tumor tissue by
reducing interstitial pressure, prevention of rapid tumor cell
repopulation during successive gemcitabine courses, and reduction
of stromal mechanisms for tumor cell progression; less likely,
augmentation of direct antitumor effects of gemcitabine is
suspected [54,55,56].
As expected, bevacizumab and EMAP as single agent did not
improve animal survival; interestingly, and in contrast to the in
vitro proliferation and local tumor growth inhibition data,
sunitinib alone did not improve survival either. This might be
due to an increased metastatic burden in this intraperitoneal
xenograft model of PDAC, or possibly mechanisms of intraper-
itoneal tumor progression that are different from local
subcutaneous settings. Importantly, gemcitabine based survival
effects were significantly enhanced by addition of single agent
bevacizumab, sunitinib or EMAP, and combinations of
gemcitabine with dual agent Bev+EMAP or triple agent
Bev+Su+EMAP were even most effective. Based on the negative
clinical trial results of gemcitabine and bevacizumab in
combination [17], our study clearly demonstrates the need for
testing combinations of gemcitabine with other, mechanistically
different antiangiogenic agents, especially multitargeted agents
such as sunitinib.
In summary, the present study demonstrates that certain
combinations of antiangiogenic agents with gemcitabine improve
in vivo antitumor effects, in accordance with differential inhibitory
effects on various cell types in vitro. Among the three antiangio-
genic agents tested, sunitinib was rather effective either alone or in
combination with gemcitabine. These results strongly corroborate
the benefits of combining polymechanistic, multi-targeting anti-
angiogenic agents with standard gemcitabine therapy for clinical
PDAC treatment. In addition, these studies indicate benefits of
selecting antiangiogenic combinations based on their mechanistic
compatibility compared with random or non-selective combina-
tions.
Figure 5. Evaluation of tumor vasculature by PECAM-1 immunostaining. Nude mice were subcutaneously injected with AsPC-1 cells
(0.75610
6) and treated with Gem, Bev, Su and EMAP, either alone or in combination, for 2 weeks. (A) Tumor tissue sections were stained with PECAM-
1 antibody and photographed under a fluorescent microscope. (B) PECAM-1 positive microvessel were counted in five different high power fields.
The data are expressed as the mean 6 standard deviation. SymbolsN and * represent significant differences (P,0.05) compared with controls and
Gem group, respectively.
doi:10.1371/journal.pone.0038477.g005
Figure 6. Animal survival time after treatment with Gem, Bev, Su and EMAP. AsPC-1 cells (0.75610
6) were intraperitoneally injected in SCID
mice, and after 2 weeks followed by treatment with Gem, Bev, Su and EMAP, either alone or in combination, for a 2-week duration. The curve
represents the animal survival time from the beginning of treatment.
doi:10.1371/journal.pone.0038477.g006
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Figure S1 Effects of gemcitabine (Gem), bevacizumab
(Bev), sunitinib (Su) and EMAP therapy on local tumor
growth. Nude mice were subcutaneously injected with AsPC-1
cell (0.75610
6). Fourteen days after tumor cell injection, therapy
was started with Gem, Bev, Su and EMAP for 2 weeks. Tumor
growth was measured twice a week using calipers. Relative tumor
volume was calculated by dividing the tumor volume at any time
by the tumor volume at the start of therapy. Data are
representative of mean values 6 standard deviation from 6–8
mice per group.
(TIF)
Figure S2 Effects of gemcitabine (Gem), bevacizumab
(Bev), sunitinib (Su) and EMAP therapy on mouse body
weight. Nude mice were subcutaneously injected with AsPC-1
cell (0.75610
6). Fourteen days after tumor cell injection, therapy
was started with Gem, Bev, Su and EMAP for 2 weeks. Mouse
body weight was measured twice a week. Data are represen-
tative of mean values 6 standard deviation from 6–8 mice per
group.
(TIF)
Figure S3 Effect of gemcitabine on in vitro cell prolifer-
ation of PDAC cells. AsPC-1, BxPC-3, MIA PaCa-2 and Panc-1
cellswereplatedon96-wellplateandtreatedwith100 nM,500 nM,
1 mM and 10 mM concentrations of gemcitabine. After 72 h, 10 ml
WST-1reagentwasaddedineachwellandincubatedfor2additional
hours. The absorbance at 450 nm was measured using microplate
reader. The resulting number of viable cells was calculated by
measuring absorbance of color produced in each well. Data are the
mean 6standard deviation of triplicate determinations.
(TIF)
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